Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

10 May 2019

Abstract excerpt

Abstract FLT3, DNMT3A, and NPM1 are the most frequently mutated genes in cytogenetically normal acute myeloid leukemia (AML), but little is known about how these mutations synergize upon cooccurrence. Here we show that triple-mutated AML is characterized by high leukemia stem cell (LSC) frequency, an aberrant leukemia-specific GPR56highCD34low immunophenotype, and synergistic upregulation of Hepatic Leukemia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31076446
DOI: 10.1182/blood.2018862383

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AMLPMID 31076446Read ↗

Distinct gene regulatory networks govern hematopoietic and leukemia stem cellsSemantic proximity Read ↗

Single cell multi-omics enables high-resolution identification and functional purification of human acute myeloid leukemia stem cellsSemantic proximity Read ↗

In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic TargetSemantic proximity Read ↗

Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse.Semantic proximity Read ↗

Broad de-regulated U2AF1 splicing is prognostic and augments leukemic transformation via protein arginine methyltransferase activationSemantic proximity Read ↗

Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressivenessSemantic proximity Read ↗

A two-step <i>in vivo</i> CRISPR screen unveils pervasive RNA binding protein dependencies for leukemic stem cells and identifies ELAVL1 as a therapeutic targetSemantic proximity Read ↗

Regulation of cell cycle by the novel GATA1/TAL1/Sphingomyelin Synthase 1 ( <i>SGMS1</i> ) transcriptional axis. Implications for anti-leukemic strategiesSemantic proximity Read ↗

Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Identification of GTF2IRD1 as a novel transcription factor essential for acute myeloid leukemiaSemantic proximity Read ↗

Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways.Semantic proximity Read ↗

RUNX1 cooperates with FLT3-ITD to induce leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.